443 articles by Jonathan Gardner
-
BioNTech, WHO hatch plan to bring mRNA vaccines to Africa
July 26, 2021 -
Biogen executives attack Aduhelm criticism, blaming 'extensive misinformation'
July 22, 2021 -
Pfizer, BioNTech ink vaccine supply deal for Africa in step toward addressing criticism
July 21, 2021 -
Merck to take on Pfizer with FDA OK of next-gen pneumonia vaccine
July 19, 2021 -
FDA advisers push back on FibroGen anemia drug
July 16, 2021 -
Lilly wagers up to $1B on a biotech's plan for a new type of insulin
July 14, 2021 -
FDA flags rare side effect in new warning on J&J's coronavirus vaccine
July 12, 2021 -
Alzheimer's Association, insurers press Medicare for coverage rules on Aduhelm
July 12, 2021 -
Sanofi dives deeper into mRNA in search for next-generation vaccines
June 29, 2021 -
Congress pressures FDA and Biogen on Alzheimer's drug approval, price
June 28, 2021 -
GSK outlines ambitious 10-year plan, but hits investors' near-term outlook
June 23, 2021 -
Merck says Keytruda extends survival in cervical cancer study
June 22, 2021 -
Long-term Zolgensma data backs up gene therapy's use in youngest patients
June 21, 2021 -
Bristol Myers partners with Eisai in $650M deal for targeted cancer antibody
June 18, 2021 -
Trial failure dashes Biogen hopes for next Alzheimer's drug
June 17, 2021 -
Former FDA chief Hahn joins venture firm that launched Moderna
June 15, 2021 -
CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder
June 15, 2021 -
As trials progress, FDA weighs COVID-19 vaccine authorizations for children
June 11, 2021 -
'The lights are no longer green': Antitrust regulators reassess pharma deals
June 10, 2021 -
Biogen Alzheimer's approval could open the door for similar drugs
June 9, 2021 -
Novo keeps price in line with FDA approval of second obesity shot
June 7, 2021 -
Alexion, AstraZeneca executives switch roles amid $39B buyout
June 4, 2021 -
Former FDA official Abernethy joins Google health spinoff
June 3, 2021 -
UniQure moves Huntington's gene therapy to next phase of key trial
May 27, 2021 -
ICER, vocal critic of drug company pricing, turns scrutiny to insurers
May 25, 2021